Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 12/20 | 0.63 |
| ▸ | HSD17B10 | Q99714 | 9/20 | 0.63 |
| ▸ | CFTR | P13569 | 1/20 | 0.63 |
| ▸ | KDM4E | B2RXH2 | 6/20 | 0.49 |
| ▸ | POLB | P06746 | 2/20 | 0.49 |
| ▸ | TSHR | P16473 | 3/20 | 0.49 |
| ▸ | HPGD | P15428 | 4/20 | 0.47 |
| ▸ | RAB9A | P51151 | 3/20 | 0.47 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.47 |
| ▸ | GLA | P06280 | 2/20 | 0.47 |
| ▸ | NPC1 | O15118 | 2/20 | 0.47 |
| ▸ | TP53 | P04637 | 1/20 | 0.47 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.47 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.47 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.47 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.47 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.47 |
| ▸ | MEN1 | O00255 | 1/20 | 0.46 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.46 |
| ▸ | NFKB2 | Q00653 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29851692 | 1.00 | ALDH1A1 (0.63) | ALDH1A1HSD17B10CFTRKDM4EPOLB | |
| Ethylene SCHEMBL27648737 | 0.96 | ALDH1A1 (0.59) | ALDH1A1HSD17B10CFTRKDM4EPOLB | |
| SCHEMBL29024770 | 0.87 | ALDH1A1 (0.61) | ALDH1A1HSD17B10CFTRKDM4EPOLB | |
| SCHEMBL1925752 | 0.86 | ALDH1A1 (0.56) | ALDH1A1HSD17B10CFTRKDM4EPOLB | |
| SCHEMBL30111657 | 0.86 | TSHR (0.50) | ALDH1A1HSD17B10CFTRTSHRRAB9A | |
| SCHEMBL109178 | 0.86 | TSHR (0.50) | ALDH1A1HSD17B10CFTRTSHRRAB9A | |
| SCHEMBL6542697 | 0.85 | ALDH1A1 (0.46) | ALDH1A1HSD17B10CFTRKDM4EPOLB | |
| SCHEMBL7064303 | 0.85 | ALDH1A1 (0.44) | ALDH1A1HSD17B10CFTRTSHRRAB9A | |
| SCHEMBL25142572 | 0.84 | HSD17B10 (0.45) | ALDH1A1HSD17B10CFTRKDM4ETSHR | |
| Hydrogen Peroxide SCHEMBL29048859 | 0.84 | TSHR (0.48) | ALDH1A1HSD17B10TSHRRAB9ANPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 233 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-115466341-B | Ashless dispersant and preparation method thereof | 新乡市瑞丰新材料股份有限公司 | 2024-12-20 | — | — | CN | claimed |
| CN-117800866-A | Synthesis method and application of 2- (3- (4-hydroxyphenyl) propionylamino) benzoic acid | 信阳师范学院 | 2024-04-02 | — | — | CN | claimed |
| CN-115466341-A | Ashless dispersant and preparation method thereof | 新乡市瑞丰新材料股份有限公司 | 2022-12-13 | — | — | CN | claimed |
| CN-114292204-A | Preparation method of dihydrooat alkaloid | 重庆美杉蓝科技发展有限公司 | 2022-04-08 | — | — | CN | claimed |
| US-20260138956-A1 | NOVEL COMPOUNDS AND USES THEREOF | RECURSION PHARMACEUTICALS INC (US) | 2026-05-21 | — | — | US | disclosed |
| US-20260130925-A1 | METHODS FOR TREATING CANCER | GENESIS MOLECULAR AI INC (US) | 2026-05-14 | — | — | US | disclosed |
| US-20260131009-A1 | BIFUNCTIONAL PI3K-ALPHA INHIBITORS AND USES THEREOF | RELAY THERAPEUTICS INC (US) | 2026-05-14 | — | — | US | disclosed |
| US-20260078120-A1 | SUBSTITUTED PYRIDOPYRIMIDINONES | Mirati Therapeutics, Inc. (US) | 2026-03-19 | — | — | US | disclosed |
| EP-4709714-A1 | SUBSTITUTED QUINOXALINES | Mirati Therapeutics, Inc. (US) | 2026-03-18 | — | — | EP | disclosed |
| EP-4705281-A1 | COMPOUNDS FOR TREATING CANCER | Genesis Molecular AI, Inc. (US) | 2026-03-11 | — | — | EP | disclosed |
| US-20250346603-A1 | TRICYCLIC COMPOUNDS AS PI3KALPHA INHIBITORS | PIKAVATION THERAPEUTICS INC (US) | 2025-11-13 | — | — | US | disclosed |
| EP-4602031-A1 | METHODS FOR TREATING CANCER | Genesis Therapeutics, Inc. (US) | 2025-08-20 | — | — | EP | disclosed |
| US-4782158-A | CEPHEM ANTIBIOTIC INTERMEDIATES | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 1988-11-01 | — | — | US | disclosed |
| US-4599426-A | INTERMEDIATES FOR CEPHALOSPORINS | FUJISAWA PHARMACEUTICAL CO. (JP) | 1986-07-08 | — | — | US | disclosed |
| EP-0059486-B1 | NEW STARTING COMPOUNDS FOR PREPARING CEPHEM COMPOUNDS AND PROCESSES FOR THEIR PREPARATION | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 1985-10-02 | — | — | EP | disclosed |
| US-4506076-A | MICROBIOCIDES, CEPHALOSPORINS | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 1985-03-19 | — | — | US | disclosed |
| EP-0009548-B1 | CEPHALOSPORIN DERIVATIVES, PROCESS FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 1985-01-16 | — | — | EP | disclosed |
| EP-0059486-A1 | New starting compounds for preparing cephem compounds and processes for their preparation | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 1982-09-08 | — | — | EP | disclosed |
| US-4288435-A | 3,7-Disubstituted-3-cephem-4-carboxylic acid compounds and pharmaceutical antibacterial compositions containing them | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 1981-09-08 | — | — | US | disclosed |
| EP-0009548-A2 | Cephalosporin derivatives, process for their preparation and pharmaceutical compositions containing them | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 1980-04-16 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260138956-A1 | NOVEL COMPOUNDS AND USES THEREOF | SLC10A1, NR3C2, CYP2C8 | ALDH1A1 230/4885HSD17B10 217/4885CFTR 53/4885 |
| US-20250346603-A1 | TRICYCLIC COMPOUNDS AS PI3KALPHA INHIBITORS | PIK3CA, PIK3CD, PIK3CB | ALDH1A1 3645/4885HSD17B10 776/4885CFTR 3260/4885 |
| US-20260131009-A1 | BIFUNCTIONAL PI3K-ALPHA INHIBITORS AND USES THEREOF | PIK3R5, PIK3R4, PIK3R1 | ALDH1A1 4550/4885HSD17B10 1338/4885CFTR 2584/4885 |
| US-20260130925-A1 | METHODS FOR TREATING CANCER | PIK3R1, PIK3R5, PIK3R2 | ALDH1A1 1755/4885HSD17B10 478/4885CFTR 437/4885 |
| US-20260078120-A1 | SUBSTITUTED PYRIDOPYRIMIDINONES | CBR1, CBR3, CNR1 | ALDH1A1 628/4885HSD17B10 991/4885CFTR 1314/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.